An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 156 participants.

Also called NCT01202058

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 156 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01202058
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Netherlands, Spain, Switzerland (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01202058. Randomized; single masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)
Acronym
NEVO II
Condition
Atherosclerotic Coronary Artery Disease
Intervention (Device)
NEVO™ Sirolimus-eluting Coronary Stent System
Intervention (Device)
XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)
Lead sponsor
Cordis US Corp. (class: industry)

Record details

Record id
cardio:ct-nct01202058
Content hash
dd4cef9d1b73ce04c9921e393e4304f5101b075b417b89a64498b63da5d05629